Quanterix reports preliminary FY2023: double-digit revenue growth, non-GAAP GM ~50%, >$300M net cash

Quanterix Corp

2023-FY EPS reported -$0.86 revenue$122,368,000

Preliminary FY2023 double-digit revenue growth; GAAP gross margin in high 50's, non-GAAP ~50% (improvement of 1200 bps).
Net cash >$300M; annual cash burn reduced by >3x.
Over 950 instruments installed; lab services capability >0.75M tests/year (up 50%); manufacturing capacity >4M tests/year (up 300%).
Innovation rate >20 assays per year; development time reduced from >18 months to <6 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quanterix Corp updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

On January 10, 2024, Masoud Toloue, the President and CEO of Quanterix Corporation (the “Company”), made a presentation at the 42 nd Annual JP Morgan Healthcare Conference. The presentation included slides (the “Slides”) containing preliminary, unaudited estimated financial information for the fourth quarter and year ended December 31, 2023 (the “Preliminary Financial Information”).

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-000191

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.